IBM and Accelrys form global strategic alliance to transform drug research and development
Armonk 07 January 2002 IBM and Accelrys Inc., a wholly owned subsidiary of Pharmacopeia Inc., have signed a global strategic alliance to enhance drug research and development (R&D) operations by creating a collaborative information technology environment for chemists and biologists to develop new drugs faster, more efficiently, and at lower costs.
Through the agreement, Accelrys, a software developer in life sciences, will become a premier partner in IBM's PartnerWorld for Developers Programme, a status reserved for top-tier strategic alliance partners.
IBM and Accelrys will team up, with each company contributing key technologies, to help pharmaceutical and biotechnology companies and medical research centres improve their R&D operations and shorten the development cycle for new drugs.
Under the terms of the four-year alliance, IBM becomes Accelrys' preferred information technology and services partner for life sciences. IBM's eServer systems will be Accelrys' server family of choice for life sciences applications.
Through its collaboration with IBM, Accelrys will accelerate the delivery of its Discovery Studio platform, which promises to be the industry's first technology platform to fully support the entire drug discovery process. Discovery Studio is a set of Accelrys technologies that will offer broad access to key life sciences applications, while enabling effective capture and reuse of critical scientific information and knowledge, whether generated by Accelrys' portfolio of software products, in-house or by third parties.
Other key elements of the alliance include:
- Accelrys will enable its software applications to run optimally on IBM eServer systems for UNIX, Windows NT and Linux. Accelrys applications, which support R&D processes
ranging from early isolation of target genes and proteins associated with particular diseases, through synthesising chemical compounds that will work on these targets, to pre-clinical testing and drug delivery, are used by virtually every major pharmaceutical and most major biotechnology and chemical companies.
- Accelrys becomes a premier member of IBM's PartnerWorld for Developers Programme, which offers
business partners a wide range of sales, education, training, and technical support programmes. This worldwide programme is designed to help software developers reach broader markets
faster and lower their costs of doing business.
- Accelrys will use IBM eServer p690, code named "Regatta", systems running AIX, IBM eServer xSeries systems running Linux and Windows NT, and the IBM eServer Cluster 1300 Linux
system for software development, testing and knowledge management applications.
- Accelrys will combine IBM DiscoveryLink data integration technology with the new Discovery Studio platform.
- IBM and Accelrys will jointly market Discovery Studio offerings for IBM platforms and middleware.
- IBM and Accelrys will provide a range of joint consulting and implementation services for deploying solutions that combine mutual technologies.
According to the TOP500 Supercomputer list, IBM systems account for 160 of the world's 500 most powerful high-performance computers and half of the top 10 more powerful machines, more than any other vendor. The list was published in November 2001 by supercomputing experts Jack Dongarra from the University of Tennessee and Erich Strohmaier and Hans Meuer of the University of Mannheim in Germany.
Ad Emmen
[News on Advanced IT]
[Calendar]
[Analysis]
[IT in Medicine]
|